Literature DB >> 21185531

HIV-infected adolescents: relationship between atazanavir plasma levels and bilirubin concentrations.

Ana P Nso Roca1, Ana P Nso, Beatriz Larru, Jose M Bellón, Maria José Mellado, Jose T Ramos, Maria Isabel González, Maria Luisa Navarro, Maria Ángeles Muñoz-Fernández, Maria Isabel de José.   

Abstract

The use of atazanavir (ATV) in adolescents infected with human immunodeficiency virus was analyzed in this study. ATV morning plasma concentrations were determined during regular visits to the outpatient department. Results showed that bilirubin levels were higher among patients with higher ATV plasma concentrations (p = .018). Monitoring plasma levels of ATV could avoid toxicity in these patients.
Copyright © 2011 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21185531     DOI： 10.1016/j.jadohealth.2010.05.009

Source DB:  PubMed          Journal:  J Adolesc Health        ISSN： 1054-139X            Impact factor:   5.012


  5 in total

1.  Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry.

Authors:  Nhi Phung; Karen Kuncze; Hideaki Okochi; Alexander Louie; Leslie Z Benet; Igho Ofokotun; David W Haas; Judith S Currier; Tariro D Chawana; Anandi N Sheth; Peter Bacchetti; Monica Gandhi; Howard Horng
Journal:  Rapid Commun Mass Spectrom       Date:  2018-03-15       Impact factor: 2.419

Review 2.  Atazanavir: in pediatric patients with HIV-1 infection.

Authors:  Emma D Deeks
Journal:  Paediatr Drugs       Date:  2012-04-01       Impact factor: 3.022

3.  Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.

Authors:  Richard M Rutstein; Pearl Samson; Terry Fenton; Courtney V Fletcher; Jennifer J Kiser; Lynne M Mofenson; Elizabeth Smith; Bobbie Graham; Marina Mathew; Grace Aldrovani
Journal:  Pediatr Infect Dis J       Date:  2015-02       Impact factor: 2.129

4.  Case Study 6: Deconvoluting Hyperbilirubinemia-Differentiating Between Hepatotoxicity and Reversible Inhibition of UGT1A1, MRP2, or OATP1B1 in Drug Development.

Authors:  Ian Templeton; Gary Eichenbaum; Rucha Sane; Jin Zhou
Journal:  Methods Mol Biol       Date:  2021

5.  A new tool for the paediatric HIV research: general data from the Cohort of the Spanish Paediatric HIV Network (CoRISpe).

Authors:  Ma Isabel de Jose; Santiago Jiménez de Ory; Maria Espiau; Claudia Fortuny; Ma Luisa Navarro; Pere Soler-Palacín; Ma Angeles Muñoz-Fernandez
Journal:  BMC Infect Dis       Date:  2013-01-02       Impact factor: 3.090
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.